Introduction
============

Ventilator-associated pneumonia (VAP) is a frequent and severe health-care associated infection. In Europe, pneumonia occur in 7.0% of patients staying at least 2 days in intensive care units (ICUs); 91% of these pneumonia are VAP \[[@B1]\]. The proportion of VAP which is preventable is debated \[[@B2]\] but there is no doubt that a serious potential for harm reduction does exist \[[@B3],[@B4]\] and VAP prevention is becoming a major patient safety issue. In the US for instance, VAP prevention has been proposed as a national safety goal \[[@B2]\].

VAP prevention requires clinical interventions (best practice guidelines) combined with non clinical interventions to ensure implementation and compliance with these guidelines.

Clinical interventions for VAP prevention fall in three categories \[[@B5]\]. The first, obvious one, is to limit exposure to mechanical ventilation by preferring non-mechanical ventilation when possible and limiting its duration when alternative options are not possible. Other prevention practices aim at reducing airways colonization (such as oral care decontamination using chlorhexidine \[[@B6]\]), or preventing aspiration \[[@B5]\] (e.g. by nursing in the semi-recumbent position, or maintaining a sufficient cuff pressure). Clinical interventions should be combined, in what is often called a "care bundle". The precise content of VAP care bundle varies between guidelines \[[@B7],[@B8]\] because the number of items in a "bundle" should be limited, some prevention practices are controversial (e.g. selective digestive decontamination), \[[@B9]\] and recommending best practice regarding such measures requires compromise and pragmatism \[[@B8]\]. There is no universally accepted "VAP care bundle". A study aiming at defining a "European care bundle" ranked VAP prevention measures by combining criteria such as the strength of the supporting evidence, ease of implementation, and expected impact \[[@B10]\]. The top 5 clinical interventions (we did not consider "trained staff" as a clinical intervention) were: 1) no ventilatory circuit change unless specifically indicated; 2) strict hand hygiene with alcohol especially before managing the airways; 3) daily sedation vacation and weaning protocol; 4) oral care with chlorhexidine; and 5) cuff pressure control at least every 24 hrs. It was beyond the scope of our study to assess the evidence behind each of these interventions, but none appears to be controversial.

Ensuring compliance with guidelines is a vast and complex field of research \[[@B11]-[@B13]\]. Common to any improvement strategy is the need for measurement; this serves evaluation purposes, measurement can also be the intervention, or a major component of it \[[@B14]-[@B16]\]. In a survey on infection control practices in the US, ICUs were only able to reduce heathcare-associated infection rates (including VAP), when they had a written policy, monitored compliance, and achieved a ≥95% compliance to all elements included in the local care bundle \[[@B11],[@B17]\]. Under the unchallenged assumption "if you cannot measure it, you cannot improve it" (Lord Kelvin, 1824-1907), we considered here that monitoring process (compliance to guidelines) and outcomes is a necessary, if not sufficient, component of any intervention aiming at decreasing VAP.

Accurate diagnosis of VAP is a challenge, because many conditions commonly encountered in critically ill patients -- such as pulmonary oedema, pulmonary hemorrhage and acute respiratory distress syndrome, can mimic the signs and symptoms of pneumonia \[[@B5]\]. Clinical diagnosis leads to treatment decisions, its primary aim is to be accurate, and it cannot be entirely standardized. By contrast measurement need primarily to be reproducible to ensure comparability of data overtime and allow evaluation of trends. Standardization is essential. Criteria for diagnosis and criteria for recording, therefore do not necessarily overlap entirely. Guidelines and definitions of VAP for recording and reporting exist in Europe \[[@B18]\] and in the United States \[[@B19]\]. Despite some changes in the US, current case-definitions are still considered useful for internal quality improvement purposes \[[@B20]\].

Our objectives were to document, using a web-based survey (1) reported VAP prevention practices in ICUs (clinical practices, and measurement) and (2) attitudes towards the implementation of a measurement system. Our primary interest laid in providing estimates at European level, but we did not define exclusion criteria based on geographical location; on the other hand country-specific results can be used to steer prevention initiatives at country level.

Methods
=======

Study population
----------------

Our target group was physicians working in ICUs. An ICU was defined as an unit meeting all the following criteria: provides facilities for invasive mechanical ventilation, and pump-controlled administration of infusion, functions 24 hours a day and 7 days a week, and there is at least one doctor immediately available at all times to deal with emergencies.

Questionnaire
-------------

We developed a questionnaire with 3 parts: 1) Characteristics of the respondent and her/his ICU, 2) VAP prevention practices (clinical, and measurement). For clinical practices we focused on the top 5 clinical components of the European VAP care bundle \[[@B10]\] and added a commonly recommended practice (head of bed elevation) \[[@B5]\]. For measurement, we included questions on measurement of process (compliance to prevention practices, average duration of intubation) and outcomes (measurement of VAP, definitions used for data collection -- European, \[[@B18]\] or American, \[[@B19]\] and the ability to report selected indicators. 3) attitudes as regards the implementation of a data collection system, using a 5 point-Likert scale (1: strongly agree, 5: strongly disagree) \[[@B13],[@B21]\]. The questionnaire was kept very short to improve participation. It was first developed and pre-tested in English, then translated into German, Italian, Spanish, Portuguese and French by intensive care doctors and/or infection control practitioners, native speakers in the targeted language. Each translation had to be independently checked by at least another native speaker doctor. We used Limesurvey 2.0, an open source web survey application, to collect the data \[[@B22]\]. Participation was anonymous.

Dissemination to target group
-----------------------------

The questionnaire was available online from April 1 to September 1, 2012. It was endorsed by the European Society of Intensive Care Medicine (ESICM), posted on their website, and the link e-mailed to all its members. We contacted national ESICM representatives and key opinion leaders and requested their support in disseminating the survey in their country. The survey was endorsed by national ICU societies in Austria, France, Belgium, the Netherlands, Italy, and Greece. It was e-mailed to all subscribers of REMI (Revista Electronica de Medicina Intensiva), \[[@B23]\] an electronic newsletter on intensive care medicine in Spanish distributed in Spain, Portugal, and Latin America.

Data analysis
-------------

Descriptive statistics were used to characterize the study sample. Using total country population (2012 United Nations estimates \[[@B24]\]) as the weight, we computed weighted European estimates including all countries which provided at least 10 completed replies. This arbitrary threshold was chosen as a compromise between the number of countries included in the European estimates, and precision of the estimation. Statistical software STATA 10 was used for the analyses *(svy* command for survey data for weighted estimates). Replies from the remaining countries, both European and non European, were simply pooled together. We choose to present uncommented, detailed country-specific results as Additional file [1](#S1){ref-type="supplementary-material"}, for use by national stakeholders.

Results
=======

A total of 1730 completed replies from 77 different countries were submitted (Table [1](#T1){ref-type="table"}). Characteristics of the respondents, and their setting, are presented in Table [2](#T2){ref-type="table"}.

###### 

Number of replies to the survey, by country

                                                           **Replies**   **%**
  ------------------------------------------------------- ------------- -------
  ***European countries***                                                  
  Spain                                                        293        17%
  France                                                       251        15%
  Italy                                                        187        11%
  Austria                                                      130        8%
  United Kingdom                                               115        7%
  Germany                                                      67         4%
  Portugal                                                     50         3%
  Belgium                                                      33         2%
  Netherlands                                                  31         2%
  Switzerland                                                  29         2%
  Greece                                                       23         1%
  Romania                                                      20         1%
  Denmark                                                      15         1%
  Sweden                                                       14         1%
  Ireland                                                      13         1%
  Hungary                                                      10         1%
  *Total European countries with at least 10 replies\**      *1281*      *74%*
  Other (18 different countries)                               55         3%
  ***Non European countries***                                              
  India                                                        63         4%
  Argentina                                                    40         2%
  Colombia                                                     31         2%
  Mexico                                                       31         2%
  Australia                                                    23         1%
  Peru                                                         23         1%
  Brazil                                                       21         1%
  Ecuador                                                      13         1%
  Chile                                                        12         1%
  Turkey\*\*                                                   12         1%
  United States                                                12         1%
  Saudi Arabia                                                 11         1%
  United Arab Emirates                                         11         1%
  Venezuela                                                    11         1%
  Other (29 different countries)                               80         5%
  **Survey - total**                                          1730       100%

\* Used for European weighted estimates.

\*\* Considered as non European as majority of population does not live in Europe.

###### 

Characteristics of the respondents, and of their setting

                             **Respondent**  **Weighted estimates for Europe (respondents from 16 countries with \>=10 replies)**   **Other respondents (61 countries)**                              
  ----------------------------------------- -------------------------------------------------------------------------------------- -------------------------------------- ------ ------ ------ ------ ----
                Years working in ICU (mean)                                          12.8                                                           12.2                   13.3   12.9   12.1   13.6  
    Admissions per year in their ICU (mean)                                          1006                                                           914                    1098   900    787    1013  
                       N beds in ICU (mean)                                           16                                                             15                     17     16    15.4   17.3  
                                                                                    *%\**                                                                                         *N*    *%*            
                           Gender (females)                                           28                                                             25                     31     82     18     15    22
      Working in hospital with \> 1000 beds                                           17                                                             14                     20     18     4      2     6
    Working in hospital with 300--1000 beds                                           55                                                             52                     56    145     33     28    37
             Working in hospital \<300 beds                                           28                                                             26                     31    282     63     58    67

\* Absolute numbers are not reported because percentages are weighted estimates.

Weighted European estimates are based on 1281 respondents from the 16 countries from which at least 10 completed replies were available.

VAP prevention practices are presented in Table [3](#T3){ref-type="table"} (clinical practices) and Table [4](#T4){ref-type="table"} (measurements).

###### 

VAP prevention: clinical practices, as reported by ICU doctors

                                                                   **Clinical practice**  **Weighted estimates for Europe (respondents from 16 countries with \>=10 replies)**   **Other respondents (61 countries)**                       
  -------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- -------------------------------------- ---- ----- ---- ---- -----
    *In my ICU, hand hygiene is done with alcohol hand rub, always, or most of the time*                                           95                                                             94                    97   395   88   85   91
                            *In my ICU, there are written guidelines for VAP prevention*                                           65                                                             62                    69   282   63   58   67
                                                            Guidelines developed locally                                           33                                                             30                    36   162   36   32   41
                                                         Guidelines developed nationally                                           31                                                             28                    34   117   26   22   30
                                    *In my ICU, care for intubated patients includes...*                                                                                                                                                       
                            No ventilatory circuit changes unless specifically indicated                                           69                                                             66                    72   371   83   79   86
               Strict hand hygiene using alcohol, especially before managing the airways                                           83                                                             80                    86   364   81   77   85
                          Systematic daily interruption of sedation and weaning protocol                                           49                                                             46                    53   285   63   59   68
                                                            Oral care with chlorhexidine                                           70                                                             67                    73   302   67   63   72
                                           Cuff pressure control at least every 24 hours                                           83                                                             81                    85   347   77   73   81
                                                                   Head of bed elevation                                           96                                                             94                    97   442   98   97   100

\* Absolute numbers are not reported because percentages are weighted estimates.

###### 

VAP prevention: measurements, as reported by ICU doctors

                                                                                              **Measurements**  **Weighted estimates for Europe (respondents from 16 countries with \>=10 replies)**   **Other respondents (61 countries)**                       
  ------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------- -------------------------------------- ---- ----- ---- ---- ----
                                                              *Measurement of compliance at least once a year*                                                                                                                                                      
                                                                                  Hand hygiene recommendations                                           57                                                             54                    60   265   60   54   64
                                                Systematic daily interruption of sedation and weaning protocol                                           28                                                             24                    33   102   23   19   27
                                                                                  Oral care with chlorhexidine                                           27                                                             23                    30   126   28   24   32
                                       *"In my ICU, there is a written definition of VAP for data collection"*                                           50                                                             47                    54   286   64   59   68
                                                                                      YES- European guidelines                                           26                                                             23                    29   37    8    6    11
                                                                                           YES- CDC guidelines                                           12                                                             10                    15   206   46   41   51
                                             *"In my ICU, we count and record, routinely..." (% saying "yes")*                                                                                                                                                      
                                                                                                           VAP                                           55                                                             51                    58   287   64   59   68
                                                                                               Intubation-days                                           81                                                             78                    84   364   81   74   85
                                                                                            Intubated patients                                           90                                                             88                    92   367   82   78   85
      *Please provide, if possible, the following data for your ICU - for part or all 2011 (% providing data)*                                                                                                                                                      
                                                                                    VAP/ 1000 ventilation-days                                           20                                                             17                    22   113   25   21   29
                                                     Mean duration of intubation for intubated patients (days)                                           27                                                             25                    30   148   33   29   37
                                                                              Proportion of intubated patients                                           38                                                             35                    41   178   40   35   44
    *"Clinical staff in my ICU is aware of VAP-related measures, and their trends" (% agree strongly / agree)*                                           53                                                             50                    56   298   66   62   71

\* Absolute numbers are not reported because percentages are weighted estimates.

Attitudes towards the implementation of a VAP measurement system are presented in Table [5](#T5){ref-type="table"}.

###### 

Attitudes towards the implementation of a measurement system of infections in ICUs

                                                                                                                          **Weighted estimates for Europe (respondents from 16 countries with \>=10 replies)**   **Other respondants (66 countries)**                                               
  ---------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- -------------------------------------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----
                                                           ***To what extent do you agree with the following comments***                                                                                                                                                                            
                                                                         If you cannot measure it, you cannot improve it                                           83                                                             80                    85   11   9    13   84   80   87   11   8    14
                                                       Monitoring of VAP related measures stimulates quality improvement                                           93                                                             91                    94   2    1    3    97   94   98   1    0    3
                                                                    VAP-related measures in my ICU (if any) are reliable                                           54                                                             51                    58   12   10   15   66   61   70   8    6    11
                                                     I am willing to implement, or support, a VAP data collection system                                           84                                                             81                    86   4    3    6    92   89   94   1    0    3
                                       Clinical diagnosis of VAP is difficult: this makes measurement systems unreliable                                           46                                                             43                    50   32   29   36   43   38   47   36   32   41
                   There is a difference between a definition of VAP for reporting, and a diagnosis of VAP for treatment                                           45                                                             42                    49   32   28   35   46   41   50   30   26   35
    ***Please indicate what actions would facilitate the implementation of a measurement system of infections in ICUs***                                                                                                                                                                            
                                                                                   Timely feed-back of data at ICU level                                           92                                                             90                    94   1    1    2    96   93   97   0    0    2
                                                                                                  Administrative support                                           88                                                             86                    90   2    1    3    95   92   97   1    0    2
                                                                                       Dedicated software / IT resources                                           91                                                             89                    93   2    1    3    92   89   94   0    0    2
                                                                                                           Reliable data                                           95                                                             93                    96   1    0    2    96   94   98   0    0    1

Discussion
==========

Key results
-----------

This is, to our knowledge, the first international survey assessing VAP prevention practices -- (clinical, and measurement) -- among ICUs doctors. Participation was large, and almost two thirds of respondents reported the existence of written VAP prevention guidelines in their ICU - pointing out the interest in, and awareness of the problem. If we combine the good clinical practice, AND measuring compliance to this practice at least once a year (a very pragmatic objective), this was reported by 57% (hand hygiene), 29% (daily interruption of sedation) and 26% (oral care with chlorhexidine) of the participants to this survey (European estimates). Interestingly, "head of bed elevation" - a practice ranked very low in the "European care bundle" because it was perceived as difficult to implement - was mentioned by 96% of the respondents; this clinical practice was known by 85% of European nurses participating in a knowledge test about VAP prevention practices \[[@B25]\].

As regards measurement of outcomes, European estimates show that only 54% count and record the number of VAP on a routine basis; and only 20% were able to provide data for their ICU on the main indicator used to monitor VAP - (VAP/1000 intubation-days). In contrast with these low proportions 93% agreed that "monitoring of VAP-related measures stimulates quality improvement" and 84% said they were willing to implement, or support, a VAP data collection system. They expressed some distrust as regards the data (46% agreed with the statement "clinical diagnosis of VAP is difficult; this makes measurement unreliable"), on the other hand, only 50% were aware of a standardized case definition for VAP recording in their ICU; and only 45% understood the difference between a definition of VAP for recording, and a diagnosis of VAP. Overall, 95% of respondents agreed that reliable data would facilitate the implementation of a measurement system.

These European estimates mask large difference between countries. For example oral care with chlorhexidine was reported by 55% (139/251) of the respondents in France, and by 94% (276/293) in Spain. Respondents saying yes to the question "in my ICU, we count and record VAP on a routine basis" were 50% (57/115) in the UK, and 74% (218/293) in Spain. Daily sedation vacation and weaning protocol were reported by 81% (93/115) in the UK, and by 35% (66/187) in Italy (see country-specific data, as Additional file [1](#S1){ref-type="supplementary-material"}).

Results from the 449 respondents not included in the European estimates are surprisingly similar to those of the European estimates.

Strengths and Limitations
-------------------------

This survey has several limitations. First, we cannot claim that participants represent a random sample of ICU clinicians in Europe nor in their own country. Some categories of ICU doctors are likely to be overrepresented, such as members of ICU national, or international societies. These might be better informed, and apply VAP prevention guidelines more than the average clinician. The list of VAP prevention measures we used as a reference for good practices guidelines \[[@B10]\] could be criticized on several grounds, e.g. it does not include subglottic secretions drainage \[[@B26]\]. Our dissemination strategy obviously worked better in some countries than others. Another limitation is that some questions in the questionnaire apply to the individual physician and others to the ICU ("in my ICU, care for intubated patients includes...) but the online questionnaire did not include questions allowing for the identification of the ICU, in order to preserve the anonymity of the respondents.

Respondents not included in the European estimates represent a very heterogeneous population with no clear geographical basis. We nevertheless considered it worthwhile to pool these results, because together these doctors are responsible for a large number of patients, and these data have identified weaknesses broadly similar to those observed in the European estimates.

Clearly, it cannot be concluded from a doctor's reporting of a clinical practice in her/his setting, that this practice is used all the time for every patient who needs it: self-reports mainly provide information regarding clinicians' knowledge of guideline recommendations, but they are subject to bias -- overestimation -- and should not be used as the sole measure of guideline adherence \[[@B27]\]. Measuring compliance to guidelines at local level once a year appears as an absolute minimum. We did not ask details on the methods used to measure compliance. This is not necessarily easy, for instance detailed guidelines exist for measuring compliance to hand hygiene recommendations; \[[@B28]\] and oral care in ventilated patients is a complex procedure that might require a check list \[[@B29]\].

It was not among the objectives of this survey to collect data on VAP incidence rate in ICUs -- there are much better sources for this -- e.g. surveillance data for Europe \[[@B1]\]. Rather we wanted to investigate the knowledge doctors had of the rates in their units. However data provided on VAP rates (not shown) are in the expected range as reported in surveillance networks \[[@B1]\], giving some validity to our results.

Interpretation
--------------

The large participation to this survey reflects the interest of the ICU community in the issue of VAP prevention. To the extent that the selection bias, and the reporting bias in our results lead to overestimating VAP prevention practices in ICUs, weaknesses identified appear robust enough as to support targeted interventions for improvement. The priority for improving care of intubated patients is promoting the clinical practices with the lowest reported use (daily sedation vacation, and weaning protocols, oral care with chlorhexidine, and no ventilatory circuit change unless specifically indicated). Improving knowledge of clinical guidelines is far from sufficient to improve practices \[[@B25],[@B30]\] but it is a prerequisite. ICUs doctors overwhelmingly agree that monitoring of VAP-related measures stimulates quality improvement but very few do it, although most are willing to do it. They could be helped to do so by learning how to produce reliable data (standardized case-definitions, methods for measuring compliance) with real-time feed-back at the ICU level; so that clinical staff could monitor their own trends over time. A compromise needs to be found between time-consuming data collection, and usefulness of data. Additional resources (human resources, information technology) might help, but some very simple measures can be implemented with minimal input, e.g. in some ICUs a panel with the number of days since last ICU-acquired infection (including VAP) is displayed on the board and updated daily (personal observations in Scotland, MLL). This study did not consider the issue of surveillance and reporting of outcome indicators at regional or national level, nor the merits (or otherwise) of evaluation of performance and feed-back, based on benchmarking (e.g. comparisons between units). Specific priorities might differ between countries.

Conclusions
===========

This survey has documented a large potential for improvement in clinical and non-clinical practices aimed at preventing VAP in ICUs. Some results, such as a large agreement of the respondents that data collection is essential -- "if you cannot measure it, you cannot improve it" - extend beyond the issue of VAP prevention. Promoting the implementation of guidelines for VAP prevention needs to be done together with promoting the measurement of compliance to these guidelines and measurement of outcomes as a tool for improvement, keeping data collection systems at ICU level as simple as possible: what is important is usefulness, not perfection \[[@B31]\].
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